医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda Selected for the Sixth Consecutive Year for Dow Jones Sustainability Asia Pacific Index

2015年09月29日 AM10:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Takeda Pharmaceutical Company Ltd. (“Takeda”) (TOKYO: 4502) has been selected for the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific) for the sixth consecutive year. Takeda has been included in the DJSI Asia Pacific since 2010 for its sustainability performance.

DJSI Asia Pacific is part of the Dow Jones Sustainability Indexes (DJSI). It is designed for companies in the developed Asia Pacific markets and comprises 145 companies, including 62 Japanese companies, that are leading the way in terms of sustainability among the 600 companies in the region. For inclusion in the DJSI Asia Pacific, Dow Jones assesses companies based on questionnaire responses, annual reports from each company and publicly available company information.

For Takeda, CSR is rooted in putting the patient in the center and operating a pharmaceutical business that creates outstanding products. The company also strives to maintain and improve sound business processes, and to engage in activities to promote a sustainable society as a good corporate citizen. In doing so, it is implementing a model of value creation and preservation through CSR. This will help Takeda to build trust with society, reinforce its reputation, and further develop the pharmaceutical business.

Takeda promotes CSR activities in line with internationally recognized guidelines, such as the United Nations Global Compact’s 10 principles. The company is also included in the FTSE4Good Global Index by the FTSE Group and the Morningstar Socially Responsible Investment Index (MS-SRI) compiled by Morningstar Japan K.K.

DJSI is one of the world’s foremost indices for Socially Responsible Investment. It assesses and selects leading sustainability-driven companies based on economic, environmental, and social criteria. Thus it serves as an important indicator for investors considering corporate social responsibility (CSR) performance. It is provided by S&P Dow Jones Indices LLC of the United States.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150928005070/en/

CONTACT

Media Contacts:
Japan based media
Takeda
Pharmaceutical Company Limited
Nanako Nakamura, +81-3-3278-2339
nanako.nakamura@takeda.com
Media
outside Japan

Takeda Pharmaceuticals International, Inc.
Jocelyn
Gerst, +1-224-554-5542
jocelyn.gerst@takeda.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表